Jan 6 2025 |
AI-Enabled Device Software Functions: FDA’s Final Guidance for Predetermined Change Control Plans |
Foley & Lardner LLP |
Jan 3 2025 |
Food & Chemicals Unpacked: Let's Pack It Up - 2024 Packaging Year in Review [Podcast] |
Keller and Heckman LLP |
Jan 3 2025 |
Federal Court Vacates APHIS GMO Movement Rule |
Keller and Heckman LLP |
Jan 2 2025 |
APHIS Restarts Permitting and “Am I Regulated” Processes for Products of Biotechnology |
Bergeson & Campbell, P.C. |
Jan 2 2025 |
What Food Product Companies Need to Know About the New Proposition 65 Warning Requirements |
ArentFox Schiff LLP |
Dec 31 2024 |
FDA Issues New Cosmetics Proposed Rule: Let’s Talk About Talc |
ArentFox Schiff LLP |
Dec 31 2024 |
FDA Sets Uniform Compliance Date for New Food Labeling Rules |
Keller and Heckman LLP |
Dec 30 2024 |
CODEX ALIMENTARIUS: Main Outcome of the 47th session (CAC47) |
Keller and Heckman LLP |
Dec 30 2024 |
Key State Laws Set to Take Effect on January 1, 2025 |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
Dec 30 2024 |
High Stakes and Political Blazes: Top 10 Cannabis Trends of 2024 |
Bradley Arant Boult Cummings LLP |
Dec 30 2024 |
FDA Sued Over Laboratory Developed Tests Final Rule |
Robinson & Cole LLP |
Dec 27 2024 |
FDA Seeks Comments on Updates to MoCRA Guidance on Registration, Listing of Cosmetic Product Facilities |
McDermott Will & Schulte LLP |
Dec 26 2024 |
CTP Advances Proposal to Set Maximum Nicotine Level in Cigarettes |
Keller and Heckman LLP |
Dec 23 2024 |
USDA Issues Streamlined Regulation for Biobased Markets (BioPreferred) Program |
Bergeson & Campbell, P.C. |
Dec 23 2024 |
ECHA Publishes Second Interim Evaluation of EUON |
Bergeson & Campbell, P.C. |
Dec 23 2024 |
Federal Circuit Decides Case Involving Orange Book Listing of Device Patents |
Polsinelli PC |
Dec 23 2024 |
USDA Reverts to Pre-2020 Regulatory Framework for Genetically Engineered Organisms Following California Federal Court Ruling |
Beveridge & Diamond PC |
Dec 23 2024 |
Social Consumption Lounges in Massachusetts: Proposed Rules |
Blank Rome LLP |
Dec 20 2024 |
The Legal and Economic Realities of Medicare Drug Pricing: Navigating Opportunities and Challenges |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 20 2024 |
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List |
Foley & Lardner LLP |
Dec 20 2024 |
FDA To Publish Final Rule Defining “Healthy” Claims |
Keller and Heckman LLP |
Dec 19 2024 |
New Accelerated Approval Guidance Underscores Need for Accountability |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 19 2024 |
FDA Finalizes "Healthy" Claims Rule |
Hunton Andrews Kurth |
Dec 19 2024 |
Ninth Circuit Precedent Limits Fraud-Based Label Claims |
Foley & Lardner LLP |
Dec 19 2024 |
First-Ever Corporate Integrity Agreement with Consulting Firm in Opioid Crisis-Related Resolution of Civil and Criminal Investigations |
Tycko & Zavareei LLP |
Dec 19 2024 |
The Best of Intentions: State Law Protections for Employee Cannabis Use May Not Protect Them After All |
Bradley Arant Boult Cummings LLP |
Dec 19 2024 |
The Grass May Not Be Greener in Texas: New Bill Seeks to Ban Hemp-Derived THC Products |
ArentFox Schiff LLP |
Dec 19 2024 |
Florida Employers Should Consider Accommodations for Off-Duty Use of Medical Marijuana, Court Rules |
Jackson Lewis P.C. |
Dec 19 2024 |
Factors Courts Commonly Consider When Deciding Motions to Transfer in ANDA Litigation |
Womble Bond Dickinson (US) LLP |
Dec 19 2024 |
The Devil Is in the Details: Bioequivalence, In Vitro Testing Not Enough to Establish Infringement |
McDermott Will & Schulte LLP |
Dec 19 2024 |
FDA Shares Testing Results for PFAS in Clams |
Keller and Heckman LLP |
Dec 19 2024 |
This Week in 340B: December 10 – 16, 2024 |
McDermott Will & Schulte LLP |
Dec 18 2024 |
FDA Targets GLP-1 Providers with Warning Letters |
Foley & Lardner LLP |
Dec 18 2024 |
National Association of Manufacturers Sends Letter to Trump Urging Regulatory Relief; Calls Out Food Traceability Rule |
Keller and Heckman LLP |
Dec 18 2024 |
November 2024 Bounty Hunter Plaintiff Claims |
Keller and Heckman LLP |